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The identification of effective new therapies for prostate cancer (PCa) requires a better
understanding of the multiple molecular interactions between tumor cells and their
associated microenvironment. In this context, galectin-1 (Gal-1) is a key molecule in
the determination of the prostatic carcinoma microenviroment; therefore, it is essential
to understand all the molecular processes in which this protein is involved. Most of the
previous studies found in the literature have focused on themicroenvironment remodeling
properties of tumor-secreted Gal-1, through its interactions with the glyco-receptors at
the cell membrane and the extracellular matrix. This report shows original aspects of the
lectin by focusing on the role of lymphocyte endogenous Gal-1 in controlling anti-prostate
tumor immunity. Using a murine preclinical model of prostate cancer, our results
demonstrate that endogenous Gal-1 in lymphocytesmodulates their proliferative rate and
cytotoxic function in conditions of high extracellular Gal-1 concentration, mainly derived
from tumor cells. In such conditions, the absence of Gal-1 in T lymphocytes potentiates
anti-tumor immune responses. Further studies demonstrated that endogenous Gal-1 in
CD4+, but mainly in CD8+T cells, acts as a negative regulator of anti-tumor immunity. In
conclusion, prostate tumors require Gal-1 in lymphocytes to evade immune responses.
This report lays the foundation for an original immunotherapy strategy for prostate cancer.
Keywords: prostate cancer, endogenous galectin-1 in lymphocytes, cancer immunotherapy, tumor
microenvironment, tumor immune escape
INTRODUCTION
Prostate cancer (PCa) is a major challenge for public health worldwide; epidemiological studies
place it as the second-screening and the fifth-leading cause of cancer death in adult men (1).
Suitable treatments currently exist for this type of cancer if detected early; in contrast, new
treatment options are required for advanced stages of the disease (2). Immunotherapy is a
validated alternative for the advanced stages of PCa, e.g., Sipuleucel-T (Provenge R©) is the first
immune-based therapy approved by the US Food and Drug Administration for this type of cancer
(3). In addition, several immunotherapy strategies are currently being evaluated for this and other
types of cancers involving active immunization against tumor-associated antigens and blocking
immune checkpoint molecules (4, 5). In this context, Galectin-1 (Gal-1) is a clue molecule secreted
by different types of cancers to promote a tolerogenic microenvironment (6). These tolerogenic
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effects occur locally at the primary tumor site but also at a
distance since Gal-1 is found soluble in plasma and is transported
inside microvesicles, such as exosomas (7). Indeed, most of the
immunological studies about Gal-1 are focused on its lectin
properties resulting from its interaction with β-galactosides and
promotion of lattice formation with membrane receptors and
extracellular matrix proteins [reviewed in (8)]. This kind of
interactions induces lymphocyte apoptosis after activation (9–
11), T cell exhaustion (7) and inhibits T-cell migration across
endothelial cells (12); actions that favor the tumor-inefficient
immune responses.
However, Gal-1 is also expressed intracellularly in several cell
types; it has been reported on transformed tumor cells (13–16),
regulatory T cells (17, 18) and antigen-presenting cells (19, 20),
where the endogenous Gal-1 plays a role as a regulator of the anti-
tumor immune responses. Effector T lymphocytes also express
endogenous Gal-1; the absence of Gal-1 in lymphocytes promotes
a Th1 response during parasitic diseases (21, 22). Few data are
available about the role of the endogenous Gal-1 in the control of
cytotoxic CD8+ T cell responses. On one hand, Gal-1 negatively
regulates CD8+ T cell expansion, survival upon activation,
and function fate (23). On the other hand, another study has
demonstrated that Gal-1-deficient mice have impaired in vivo
anti-viral CD8+ T cell–mediated immune responses (24). There
are no data about the role of endogenous Gal-1 expressed by
CD8+ T lymphocytes in the control of the anti-tumor properties.
However, translating the second concept, in which the absence
of Gal-1 impairs immune cytotoxicity, seems controversial, due
to the compelling evidence in the literature. In fact, Lgals1-/-
mice have Foxp3+ Treg cell suppressive dysfunction (17) and
are prone to autoimmunity (10, 19, 25–27). More interestingly,
the injection of tumorigenic cell lines into Lgals1-/- mice
demonstrated reduction of tumorigenesis (28, 29), proving the
relative importance of the stroma (including immune cells) in
determining tumorigenesis potential. Given this scenario, this
research aimed to challenge the role of Gal-1 as an endogenous
modulator of T cell properties in PCa. Although expressed at low
levels in lymphocytes, endogenous Gal-1 plays a major role in the
control of the lymphocyte anti-tumor functions in a PCa context.
The results allow us to propose themodulation of the endogenous




Animal procedures complied with the Guidelines for theWelfare
of Animals in Experimental Neoplasia (UK) and approved by the
University of Buenos Aires’s Institutional Animal Care and Use
Committee (IACUC; FCEN protocol #2014-038). Six to eight-
week-old male C57BL/6 mice were housed in the animal facility
Abbreviations: PCa, prostate cancer; Gal-1, Galectin-1; TRAMP-C1, prostate
tumor cell line used in this preclinical model; WT, wild type mice; Gal-1 KO
(Lgals1-/-), Galectin-1 deficient mice; AOD, average stage of division; CFSE,
Carboxyfluorescein succinimidyl ester used to trace cell division by flow cytometry;
Th, T helper profile of the immune response; DC, dendritic cells; Treg, regulatory
T cells; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis;
BAIM: brachial, axillary, inguinal and mesenteric lymph nodes.
of the School of Sciences, University of Buenos Aires (Argentina).
Lgals1-/- mice (originally produced by Dr. F. Poirier, France),
were provided by Dr. Gabriel A. Rabinovich (Argentina). Ly5.1
C57BL/6 (CD45.1) mice were provided by Dr. Sophie Ezine
(CNRS CDTA; Orleans, France). Athymic nude Foxn1nu mice
were acquired from the animal facility of the Veterinary School,
National University of La Plata (Argentina).
Cell Culture
Murine PCa cell line TRAMP-C1 (obtained from ATCC)
was cultured in Dulbecco’s Modified Eagle Medium (DMEM;
Invitrogen), 10% heat-inactivated FBS (Gibco), antibiotics (1
U/ml penicillin, 1µg/ml streptomycin, 2.5 ng/ml amphotericin)
and 0.25U/ml Insulin (Humulin N; Eli Lilly and Co). Cell
morphology was routinely evaluated, and cells were periodically
examined for androgen sensitivity (MTT assay) and mycoplasma
contamination (PCR). Lymph node cell primary cultures were
carried out in proliferation medium: RPMI1640 (Invitrogen)
containing 10% heat-inactivated FBS (PAA), 1 unit/mL
penicillin, 1µg/mL streptomycin, 2.5 ng/mL amphotericin B,
2mM L-glutamine and 2× 10−5 M β-mercaptoethanol.
Stable Gal-1 downregulated TRAMP-C1 cell line was
produced by transduction with a shRNA lentivirus previously
reported (30). Briefly, after 1 week, transduced (GFP+) cells
were purified by cell sorting using a FACSAria II cytometer (BD
Bioscience). Purification of the transduced cells was carried out if
GFP+ cells did not exceed 20%, in order to minimize the number
of viral integrations and thus guarantee a minimum perturbation
of the genome. As previously reported, this shRNA sequence
produced 85% of Gal-1 down-regulation at the protein level.
Murine Samples
Lymph node (brachial, axillary, inguinal and mesenteric;
BAIM) samples were harvested and single-cell suspensions were
obtained by mechanical disruption.
Cell Purification and Immunoblotting
CD3+T lymphocytes were purified (>98% purity) by cell sorting
(FACSAria; BD Biosciences) using PE labeled anti-CD3 mAb
(1452C11, BD Pharmingen). Antigen presenting cells (APC)
were purified by adherence to plastic (>90% CD14+ purity).
TRAMP-C1 cells were obtained from an exponentially growing
culture. Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer [50 mmol/L Tris–HCl pH 8, 150 mmol/L NaCl,
1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS, 10 mmol/L
EDTA, 1 mmol/L sodium vanadate, and Protease Inhibitor
Cocktail Set III (Calbiochem)]. Equal amounts of protein (20µg)
were resolved by 15% SDS- PAGE, blotted onto polyvinylidene
difluoride (PVDF) membranes (GE Healthcare), blocked with
5% bovine serum albumin (BSA, Sigma-Aldrich), and probed
with anti-galectin-1 (H-45 1:500, Santa Cruz) or anti-β-actin
(H196 1:1,000, Santa Cruz) antibodies. Specificity of the used
antibodies had been previously evaluated by immunoblotting
(30, 31). Bound antibodies were detected with peroxidase-labeled
anti-rabbit total immunoglobulins (1:3,000; Sigma-Aldrich).
Peroxidase activity was detected using a luminol-based method
and chemiluminescence was determined using a Fuji Photo Film
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Analyzer. Images were analyzed using ImageJ software (NIH,
USA).
Lymphocyte Proliferation, Apoptosis and
Degranulation Assays
For T-cell proliferation assays, 5 × 105 CFSE-stained murine
lymph node cells (2.5µM, 5min; Sigma-Aldrich) were seeded
in a 96-well U-bottomed plate in proliferation medium. To
obtain optimal co-stimulation, 10% APC (adherent splenocytes,
5 × 104) was added to each well. 1 × 104 mitomycin-arrested
TRAMP-C1 cells (3-h treatment, 10µg/ml; Sigma-Aldrich) were
added into cultures to mimic a tumor microenvironment. For
T-cell proliferation, cells were stimulated for 72 h with coated
anti-CD3 antibody (1µg/ml; 145-2C11 purified mAb) and
proliferation assessed by CFSE dilution. In the case of experiences
with purified cells, CD4+ and CD8+ T cells were purified
to homogeneity (>95% purity) by cell sorting (FACSAria,
BD Biosciences) using fluorescent-conjugated mAbs (anti-CD8,
clone 53-6.7, anti-CD4 clone GK1.5; anti-CD3 clone 1452C11;
all from BD Pharmingen), mixed at a 2:3 CD8:CD4 ratio and
cultured in presence of APC, tumor and anti-CD3 stimuli as
before. For transwell assays, 250,000 lymph node cells from
Lgals1-/- and WT mice were co-cultivated separated by a 0.4µm
pore size transwell system (Falcon). The low chamber was loaded
with 250,000 KO lymphocytes, 2,500 TC-1 and 25,000 spleen
adherent cells (APC) whereas the top chamber of the transwell
was loaded with 250,000 WT (CD45.1); 2,500 TC-1and 25,000
APC cells. Lymphocytes were activated by 0.25µg/ml anti-
CD3 mAb (145-2C11, used soluble to activate T cells in both
chambers). After 72 h of co-culture the membrane were removed
and the lymphocyte proliferation were assess by CFSE dilution in
the CD8+ CD45.2+ gate. In all cases, average stage of division
(AOD) was calculated as before (23). Briefly, percentage of cells
in each CFSE division was calculated on live CD8+ T cells and
inserted into the following equation:
AOD = {[(% undivided) + (2 × % division 1) + (3 × %
division 2)+ xxx)]/100} – 1.
Apoptosis was determined by Annexin V (BD Pharmingen)
staining, performed as before (32). For T-cell degranulation,
cells were stimulated for 48 h with coated anti-CD3 antibody
(1µg/ml; 145-2C11) and anti-CD107a was added (1 h, 37◦C;
1D4B, BD Pharmingen) followed by an additional 4 h-culture
with monensin (3µM, Sigma-Aldrich). In all the cases, cells
were then stained for CD8 (53-6.7, BD Pharmingen) in staining
buffer (PBS 1% FBS, 0.01% sodium azide) for 30min on ice.
Flow cytometric analysis was performed in a FACSAria (BD
Biosciences) and analyzed using the FlowJo software.
Generation of Experienced Anti-tumor
Lymphocytes
Dendritic cells (DC) were prepared from C57BL/6 bone marrows
as previously described (33). Briefly, bone marrow cells were
flushed with ice-cold PBS and erythrocytes lysed using ACK
buffer (8.7 g/L NH4Cl, 1g/L KHCO3, 0.05mM EDTA, pH
7.3). Cells were cultured in DMEM 20% heat-inactivated FBS
(Gibco), 1mM sodium piruvate, 2mM glutamine and antibiotics
(1 U/ml penicillin, 1µg/ml streptomycin) (Invitrogen), in
presence of 20 ng/mL mrGM-CSF and 10 ng/mL mrIL-4
(ImmunoTools). Cells were cultured for 5 days, with addition
of GM+IL-4 every 2 days. Immature DCs were pulsed during
5 h with TRAMP-C1 lysates (4 freeze/thawing steps), and
then matured with 2 ng/mL CpG-1826 (phosphorothioate
5’-TCCATGACGTTCCTGACGTT-3’, IDT) and 20µg/mL
Poly-U (Sigma-Aldrich) during an overnight culture. To obtain
experienced anti-tumor lymphocytes, wild type or Lgals1-/- mice
were s.c. immunized with tumor lysate-pulsed dendritic cells. At
day 7 pot-immunization, lymphocytes obtained from axillary,
brachial and inguinal lymph nodes were used for immune
reconstitution of nude mice.
Tumor Model in Nude Mice Reconstituted
With Wt or Lgals1-/- Experienced
Lymphocytes
Six to eight-week-old male nude mice were i.v. reconstituted with
immune cells from one experienced wild type or Lgals1-/- mice.
The day after reconstitution, 1× 106 TRAMP-C1 cells (log phase
of growth) were s.c. injected in mice in Matrigel (4–5 mg/ml;
Corning). No changes in mice weights were detected during the
protocol. Euthanasia was practiced when tumor volume reached
2500 mm3. Tumor size was measured every 2 days with caliper
and calculated asW2 × L/2, whereW = width and L= length.
Statistical Analysis
At least three biological replicates (i.e., independent experiments)
were carried out in each case, unless stated otherwise. Data
represent mean ± SD. Prism software (GraphPad) was used.
Two groups were compared with the Student t-test for unpaired
data (two-sided tests). P < 0.05 was considered statistically
significant.
RESULTS
Endogenous Gal-1 in Lymphocytes
Negatively Regulates Their Functional
Properties in a Tumor Context
A vast literature in different animal models and experimental
design are found describing the tumor cells as the main
producer of Gal-1 (13, 15, 34–44). Regarding PCa, we previously
described that Gal-1 is expressed at high levels in several
human PCa cell lines and, more importantly, in patient
prostatectomies, being upregulated during disease progression
(30, 45). Gal-1 is also highly expressed in murine TRAMP-
C1 cells (Figures 1A,B) and the downregulation of Gal-1 in
these cells by RNAi reduces their immunosuppressive potential.
In fact, the in-vitro polyclonal activation of lymphocytes in
the presence of Gal-1 downregulated TRAMP-C1 led to higher
proliferation of CD8+T cells (Figure 1C). Consequently, Gal-1
is an important immune escape mechanism activated by the
tumors.
Besides tumor cells themselves, other cells in the tumor
associated microenvironment play fundamental roles in the
determination of the tumor evolution. Understanding how
endogenous Gal-1 in each of these cells affects their own
properties seems, therefore, essential to have a complete
functional picture of the PCa microenvironment. In particular,
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FIGURE 1 | Comparison of Galectin-1 expression in immune cells. Gal-1 is
detected by western blot in purified immune subpopulations. T lymphocytes
were purified from lymph nodes, antigen-presenting cells from spleens. The
specificity of the technique was verified using Lgals1-/- cells. Additionally,
Gal-1 levels in TRAMP-C1 cells are comparatively shown. 20 µg of protein
was resolved on 15% SDS-PAGE and blotted with commercial anti-Gal-1
antibodies. (A) Representative immunoblot (n = 3). (B) Mean Gal-1 levels in
the three independent experiments. The results are expressed as Gal-1/β-actin
ratio. (C,D) Immunosuppressive effect of endogenous Gal-1 expression in
TRAMP-C1 tumor cells and in lymphocytes. Lymphocytes harvested from wild
type (C) or Lgals1-/- (D) mice were polyclonaly activated in presence of 10%
wild type APC and 1% of control or modified TRAMP-C1 tumor cells.
Proliferation was measured at 72 h by CFSE dilution. Black line: TRAMP-C1
cells with downregulated Gal-1 (stable transduced, 90% of Gal-1
down-regulation-data not shown-). Gray line: TRAMP-C1 cells transduced
with a control lentivirus. Representative of two independent experiences.
little is known about the endogenous role of Gal-1 in immune
cells. Therefore, we first checked whether Gal-1 is expressed
in immune cells and compared its expression levels with
those observed in tumor cells. Interestingly, the expression
levels of Gal-1 in immune cells [T lymphocytes and antigen
presenting cells (APC)] were considerably lower (10–20 times
less) than those of tumor cells (Figures 1A,B). Low levels of
Gal-1 expression in immune cells do not indicate a priori
that lymphocyte endogenous Gal-1 does not play any role as
an intrinsic modulator of their properties. Thus, we decided
to design an in vitro experimental model where the function
of Lgals1-/- lymphocytes would be compared with the wild-
type (WT) ones in the presence or absence of wild type
tumor (responsible of secreting high levels of “exogenous
Gal-1”). As readout, we focused on the function of CD8+
T lymphocytes, as these cells are critical in the anti-tumor
cytotoxic response (46). Our results demonstrate that without
endogenous Gal-1, CD8+ T cells showed higher proliferative
rates (Figure 2). A detailed analysis of these results shows that,
in the absence of tumor, there was a trend toward greater
proliferation of Gal-1-deficient CD8+ T lymphocytes mainly
at low conditions of stimulation (Figures 2A,B, 1µg/mL anti-
CD3). However, the results were considerably more significant
in the presence of an immunosuppressive microenvironment
generated by the tumor cells (Figures 2C,D); the absence of
endogenous Gal-1 led to higher CD8+ T cell proliferative
capacity even in such conditions. We highlight that, the major
source of extracellular Gal-1 in these experimental settings are
tumor cells that almost saturate the extracellular medium by
the secretion of high quantities of Gal-1 [dosed by ELISA
at levels of 20 ng/mL, supported also by the high cellular
levels of Gal-1 shown in Figure 1, and evaluated in patients
in our previous study (30) and reported at high levels in
the serum of cancer patients (47–50)]. The most potent
abrogation of tumor-immunosuppression was achieved by the
absence of endogenous Gal-1 in lymphocytes combined with
the down-regulation of Gal-1 in tumor cells (Figures 1C,D).
While the immune effects of Gal-1 in tumor cells have been
extensively evaluated (13–15, 51), the endogenous effect of
Gal-1 effect in lymphocytes is original and requires more
understanding.
Since a widely described action of exogenous Gal-1 is
the induction of cell death on activated T lymphocytes (9),
we evaluated if lymphocytes with no endogenous Gal-1 were
differentially induced into apoptosis in our tumor experimental
model. Figure 2E shows the percentage of apoptotic cells
determined by Annexin V staining inside the CD8+ T cell
subpopulation, and Figure 2F shows the same staining inside
each peak of division of CD8+ T cells. Altogether, these results
indicate that the absence of endogenous Gal-1 in CD8+T
lymphocytes protects these cells from apoptosis in the presence
of tumor cells. As in proliferative studies, the major source of
extracellular Gal-1 was the tumor.
Degranulation is a prerequisite to perforin-granzyme-
mediated cytotoxic function by responding to antigen-specific
CD8+T cells. The lytic granules are surrounded by a lipid
bilayer containing numerous lysosomal-associated membrane
proteins (LAMPs, CD107a and b); thus, labeling responding
cells with anti-CD107 antibodies and measuring their expression
by flow cytometry can directly identify degranulating CD8+
T cells. The results shown in Figure 3 demonstrate that
the absence of endogenous Gal-1 in CD8+ T lymphocytes
increases their ability to degranulate. This was also observed
in conditions without tumor cells and at different percentages
of TRAMP-C1 (Figure 3 and data not shown). Interestingly,
endogenous Gal-1 in lymphocytes affects not only their
percentages of degranulating cells (Figure 3A), but also
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FIGURE 2 | Role of endogenous Galectin-1 in the proliferation and activation-induced cell death of CD8+ T cells. Proliferation rates of wild-type and Lgals1-/- CD8+
T lymphocytes are compared upon activation with different anti-CD3 concentrations in a 72 h proliferation assay. (A,B) In the absence of TRAMP-C1 tumor cells.
(A) Representative CFSE dilution proliferative experience. (B) Graph bars indicating the average stage of division obtained from three independent experiences; White
bars: wild-type cells; Black bars: Lgals1-/- cells (*p < 0.05, t-test). (C,D) In the presence of 1% TRAMP-C1 tumor cells. (C) Representative CFSE dilution proliferative
experience. (D) Graph bars indicating the average stage of division obtained from three independent experiences; White bars: wild-type cells; Black bars: Lgals1-/-
cells (*p < 0.05, t-test). (E) Role of endogenous Galectin-1 in the apoptosis of CD8+ T cells upon polyclonal activation in the presence of 1% TRAMP-C1 cells.
Apoptosis rates of wild-type (n = 3) and Lgals1-/- (n = 3) lymphocytes are comparatively analyzed by Annexin V staining inside total CD8+ T cell gate (E) or inside
each peak of division (CFSE) in the CD8+ T cell gate (F). White bars: wild-type cells; black bars: Lgals1-/- cells (*p < 0.05, t-test).
the CD107a mean fluorescence intensity (MFI). This last
result indicates that the intrinsic expression/exposition
of CD107a is regulated by this lectin on a per cell basis
(Figure 3B). Altogether, these results imply that endogenous
Gal-1 in CD8+T cells an impotant role in the control
of their function, particularly in the presence of tumor
cells.
Lymphocyte Endogenous Gal-1 Modulates
Their Function Independently of
Exogenous Factors
To evaluate if the immunosuppressive role of lymphocyte
endogenous Gal-1 involves cell-to-cell contacts or the production
of soluble factors, we performed transwell experiments. Figure 4
shows that Gal-1 deficient lymphocytes proliferate more
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FIGURE 3 | Role of endogenous Gal-1 in the degranulation capacity of CD8+
T lymphocytes. T lymphocytes from wild-type (empty circles and diamonds) or
Lgals1-/- (filled circles and diamonds) mice were cultured in the presence of
WT APC and 1% TRAMP-C1 tumor cells. Lymphocytes were stimulated by
the CD3 receptor agonist antibody. After 48 h, the mobilization of CD107a was
evaluated by flow cytometry. (A) Percentage of CD8+ T cells expressing
CD107a. (B) CD107a mean intensity fluorescence (MFI) in CD8+ T cells
(*p < 0.05, t-test).
extensively than wild-type ones when activated in the presence
of tumor (as in Figure 2). We next co-cultured wild-type and
Gal-1 deficient lymphocytes (they differed in the expression
of CD45 isoform; both were activated and proliferation was
evaluated in CD45.2+ CFSE labeled). The presence of wild-type
cells reduced the proliferation of Gal-1 deficient CD8+T cells.
However, when these two lymphocyte sources were separated
through a transwell membrane, such a reduction in proliferation
was no longer observed (Figure 4). This experiment clearly
demonstrates the fundamental role of endogenous lymphocyte
Gal-1 in controlling their function upon activation, a phenomena
that is independent of the tumor secretion of Gal-1 and can
be controlled through lymphocyte-lymphocyte interactions. This
introduces new variants for the current understanding of the role
of Gal-1 in defining a tumor-associated tolerogenic context.
Gal-1 Negatively Regulates in vivo
Immunity Against PCa
Previously, it has been reported that several tumor cells lose their
tumorigenicity when injected into Lgals1-/- mice, compared with
their injection into wild-type mice (28, 29). We obtained the
same behavior in the case of the TRAMP-C1 prostate tumor
model. In fact, while 92% of wild-type mice injected s.c. with
TRAMP-C1 cells developed tumors (lag time: 47± 5; duplication
time: 7 ± 2 days, n = 5), no Lgals1-/- mice (0/4) developed
tumors after up to 80 days. However, the conclusions obtained
from this type of experimental model are complex, and the real
impact of immune-mediated effects cannot be established since
Gal-1 is absent in all cells of the body, including endothelial cells
in which it was previously demonstrated Gal-1 plays a major
regulatory role. To evaluate more precisely whether endogenous
Gal-1 in lymphocytes affects the capacity of mice to control
tumor growth under in vivo settings, we developed the following
experimental procedure: anti-tumor lymphocytes were induced
by the immunization of Lgals1-/- and wild-type mice with
dendritic cells pulsed with TRAMP-C1 lysates. At day 7 post-
immunization, immune cells were obtained from the BAIM
lymph nodes; no significant phenotype changes were detected
at this stage (total absolute cell numbers, %CD4+, %CD8+,
%CD4+CD25+Foxp3+Tregs; data not shown). Lymphocytes
obtained from the lymph nodes of immunized mice (wild type
or Lgals1-/-) were then transferred into an immunodeficient
nude mouse (1-to-1 mice ratio). Under such reconstitution
settings, all non-immune host compartments (e.g., stroma and
particularly endothelial cells) expressed Gal-1 at normal levels,
with the exception of T lymphocyte (transferred) cells. This
system allowed us to compare the ability of Lgals1-/- and wild-
type lymphocytes to control tumor growth in a WT micro-
and macro-environment. An in-depth comparison analysis
demonstrated thatmice reconstituted with Lgals1-/- lymphocytes
showed a marked increase in tumor latency and a slight decrease
in tumor duplication time (Figure 5 and Table 1). In contrast,
tumorigenesis, defined as the percentage of mice developing
tumors, was 100% in both experimental groups, implying that
endogenous Gal-1 on lymphocytes plays an important role
in controlling tumor growth in initial phases, but later other
molecular pathways can circumvent its action.
Cellular Mechanisms Involved in
Lymphocyte Modulation by Endogenous
Gal-1
Considering the previous in-vitro and in-vivo results, we analyzed
the impact of the endogenous Gal-1 absence in the different
subpopulations of cells involved in the immune response. For
this purpose, we purified APC, CD4+, and CD8+ T cells to
homogeneity and performed in-vitro proliferation assays by
mixing the subpopulations of different genotypes in fisiological
proportions. The results shown in Figure 6 demonstrate that
the absence of Gal-1 in CD4+ and CD8+ T cells results in
higher proliferative rates of CD8+ T lymphocytes. Higher effect
was observed when Gal-1 was absent in the responding CD8+
T cells compared to CD4+ T cells or all wild-type immune
cells (AOD = 1.7 vs. 1.1 or 0.8, respectively); however, maximal
CD8+ T cell proliferation occurs when Gal-1 is absent in both
lymphoid subpopulations (AOD = 2.8). The absence of Gal-1 in
APC did not produce any change in the proliferative potential
of CD8+ T lymphocytes (data not shown). Altogether, these
results clearly demonstrate that endogenous Gal-1 regulates the
functional properties of CD4+ and CD8+ T cells.
DISCUSSION
The pleiotropic functions of Gal-1 are partly due to the complex
cellular distribution of this lectin. At the extracellular level, Gal-1
is able to interact with glycosylated receptors (through their N-
acetyllactosamine glycans), thereby forming complex membrane
lattices [reviewed in (52)]. Through this outside-in process, Gal-1
regulates several cellular properties, acting as a negative regulator
of immune responses [reviewed in (53, 54)]. Consistently, most
of the current Gal-1-based immune strategies proposed for
autoimmunity and cancer are focused at the extracellular level.
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FIGURE 4 | Endogenous Gal-1 regulates lymphocyte proliferation through cell-to-cell contacts. Lymphocytes from Lgals1-/- (black bars) and wild type (white bars)
mice were polyclonally activated in presence of 1% TRAMP-C1 cells and 10% APC. Additionally, Lgals1-/- (CFSE labeled) and wild type (CD45.1; CFSE-) lymphocytes
were co-cultured together or separated through a transwell. In all cases activation was performed by 0.25µg/ml soluble anti-CD3 mAb. Proliferation was evaluated at
72 h by CFSE dilution in the CD8+ CD45.2+ gate. Results are expressed as average stage of division (AOD) and represent the mean + SD of three experiences.
Statistic significance **p < 0.01 (Student t-test).
FIGURE 5 | Endogenous Gal-1 in lymphocytes accelerates in vivo TRAMP-C1 tumor growth. Adult male nude mice were reconstituted with experienced immune cells
from wild-type (white squares; n = 5) and Lgals1-/- (black circles; n = 6) mice. The day after, the mice received 1 × 106 TRAMP-C1 in Matrigel®, and tumor growth
was monitored by volume measures. **p < 0.01, t-test.
TABLE 1 | Different Tumor Growth on Nude Mice Reconstituted with
Gal-1-deficient or competent lymphocytes.
Latency (days) Duplication time (days)
WT lymphocytes 32 ± 2 6.0 ± 1.2
Lgals1-/- lymphocytes 54 ± 4 8.2 ± 0.4
Additionally, the intracellular regulation of Gal-1 is expected
to perform extra regulatory functions. At this subcellular
localization, Gal-1 regulates several cellular processes, such as
growth, survival, and differentiation; several of these effects
are carbohydrate-independent [reviewed in (52)]. It has been
demonstrated that the downregulation of the endogenous
Gal-1 expressed by tumor cells has a direct effect on
the immune response [our results and (13–15, 51)]. As
expected, these strategies also modify the extracellular levels
of Gal-1 (38), as the transformed cells are the main Gal-
1 producers. Interestingly, Gal-1 is also expressed by other
cells of the tumor microenvironment; the endogenous function
of Gal-1 in those cells may affect tumor growth. Indeed,
several reports have demonstrated the decreased tumorigenic
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FIGURE 6 | Cellular mechanisms involved in the antitumor effect of lymphoid
endogenous Gal-1. Wild-type and Lgals1-/- CD4+, CD8+ (cell sorted, purity
>98%), and APC (adherence, purity CD14+ >90%) were combined and
co-cultured with 1% TRAMP-C1 tumor cells. The lymphocytes were activated
with anti-CD3mAb. The proliferative rates of CD8+ T cells in different cellular
combinations were evaluated by CFSE-dilution in a 72-h essay. AOD: average
of division. One experiment out of three with similar results is shown.
potential of various tumor cell lines when injected into
Gal-1-deficient mice (28, 29). The absence of Gal-1 on
endothelial cells of Lgals1-/- hosts is responsible for the loss
of tumorigenicity; angiogenesis defaults prevent an adequate
supply of nutriments, oxygen, and hormones, factors that are
essential for optimal tumor growth (28). While this report
does not exclude the importance of this scenario, it proposes
a complementary alternative in which tumors require Gal-1 to
be endogenously expressed in T lymphocytes to escape from
immune attack.
In fact, our results demonstrate that lymphocytes isolated
from Gal-1-deficient mice have higher CD8+ T cell proliferative
rates and effector functions, even when activated in the presence
of high levels of extracellular Gal-1 secreted by tumor cells. This
biological observation could be due to a direct endogenous effect
of Gal-1 on CD8+ T cells or through indirect effects on other
cell types; this report dissected the functional role of endogenous
Gal-1 in immune cells. Our results show that the expression of
Gal-1 on antigen-presenting cells is indifferent at potentiating
CD8+ T cell functions. However, the absence of Gal-1 in CD4+T
cells induced higher levels of CD8+ T proliferation. Gal-1 plays
a fundamental role in the control of differentiation and function
of conventional CD4+CD25+Foxp3+ Tregs (17). While we did
not detect changes in the frequency of Tregs in our experimental
settings (data not shown), such Tregs are functionally deficient
(17). Consequently, CD4+T cell subpopulations from Lgals1-/-
andwild-typemice differ at least at this functional level. However,
other endogenous modifications are also plausible in the CD4+T
cell compartment, as was previously demonstrated in parasitic
models of infection (21, 22). More interestingly, the absence
of endogenous Gal-1 induces higher functional properties of
CD8+ T cells. These results agree with a previous report that
demonstrated that Gal-1 has a major impact over proliferation
burst, lymphocyte survival upon activation, and effector fate
(23).
Mechanistically, our transwell experiments demonstrated
that the immunoregulation mediated by endogenous Gal-1 in
immune cells involves cell-to-cell interactions. In fact, the co-
culture of Gal-1 deficient together with wild-type lymphocytes
abolished the immunopotentiation observed in Lgals1-/- cells
alone. In addition, our results demonstrate that soluble factors
are not involved in this type of regulation. Altogether, these
results led us to hypothesize that Gal-1 deficient lymphocytes
lack immune-inhibitory membrane receptors (or, alternatively,
acquire immune-activating receptors) that have a direct effect
on lymphocyte function. It has been reported that intracellular
Gal-1 could affect cell behavior through regulation of the
transcriptional machinery (Gal-1 forms part of the spliceosome),
miRNA, and signaling pathways (52). Effects coming from
intracellular Gal-1 interactors in lymphocytes have not yet been
investigated.
Interestingly, the relevant roles of lymphocyte endogenous
Gal-1 have recently been proposed in active systemic lupus
erythematosus. In fact, patient lymphocytes demonstrate lower
levels of endogenous Gal-1 upon activation, a mechanism
that may make them prone to autoimmunity (55). In cancer,
our results support a scenario where the high levels of
exogenous Gal-1 produced by tumor cells are not enough
to evade immune attack; tumors require additional licensing
by lymphocyte endogenous Gal-1 to be efficiently immune-
suppressive. These results define a new and potent target for
immunotherapy in PCa. From a clinical point of view, it
is interesting to note that the immunopotentiation resulting
from the downregulation of Gal-1 in lymphocytes is more
significant in the presence of a tumor; consequently, an anti-PCa
therapeutic strategy based on these results should have few side
effects.
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